Crescent Biopharma
CBIO
58 hedge funds and large institutions have $286M invested in Crescent Biopharma in 2025 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 17 increasing their positions, 9 reducing their positions, and 6 closing their positions.
283% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 6
112% more capital invested
Capital invested by funds: $135M → $286M (+$151M)
89% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 9
41% more funds holding
Funds holding: 41 → 58 (+17)
20.07% more ownership
Funds ownership: 67.44% → 87.52% (+20%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$34.6M |
| 2 |
FIS
FCPM III Services
Naarden,
Netherlands
|
+$21.4M |
| 3 |
VPC
Vestal Point Capital
New York
|
+$19.1M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$17.3M |
| 5 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$17.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
-$5.36M |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$3.25M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.38M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$2.38M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.28M |
CBIO Hedge Fund Activity: Q4 2025 in Review
58 of the 8,281 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q4 2025, worth a combined $286M — up 112% from $135M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new CBIO positions and 6 closed out — a net gain of 17 holders — while 17 added to existing stakes and 9 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $34.6M. The largest seller was Commodore Capital, exiting entirely with an estimated $5.36M sold.
- 58 institutional investors held Crescent Biopharma (CBIO) as of Q4 2025, up from 41 in Q3 2025.
- Funds reported $286M of Crescent Biopharma stock for Q4 2025, up 112% quarter-over-quarter.
- 23 funds opened new Crescent Biopharma positions in Q4 2025 and 6 closed out, a net change of +17 holders.
- The largest Crescent Biopharma buyer in Q4 2025 was Fidelity Investments, an estimated $34.6M added.
- The largest Crescent Biopharma seller in Q4 2025 was Commodore Capital, an estimated $5.36M sold.
Based on aggregated 13F filings for Q4 2025.